Understanding Insulin Resistance in Type 2 Diabetes

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia resulting from progressive insulin resistance and impaired insulin secretion. Insulin resistance refers to a reduced sensitivity of target tissues — primarily muscle, adipose tissue, and the liver — to the biologic actions of insulin. Under normal conditions, insulin facilitates glucose uptake into muscle and adipose cells, suppresses hepatic glucose production, and regulates lipid metabolism. When cells become resistant, the pancreas compensates by increasing insulin secretion. Over time, beta-cell dysfunction leads to inadequate insulin production, and blood glucose levels rise. This state of chronic hyperglycemia contributes to microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular disease (cardiovascular events, stroke, peripheral artery disease). Managing insulin resistance is therefore a cornerstone of T2DM treatment. Among the pharmacologic options available, thiazolidinediones (TZDs) uniquely target insulin resistance by directly improving the body’s sensitivity to its own insulin. This mechanism sets them apart from secretagogues or injectable therapies that bypass the root defect.

How Thiazolidinediones Work: The PPARγ Pathway

Thiazolidinediones, including pioglitazone and rosiglitazone, are synthetic ligands of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor highly expressed in adipose tissue and also present in muscle, liver, and vascular cells. PPARγ forms a heterodimer with the retinoid X receptor (RXR) and, upon activation, binds to specific DNA response elements to regulate transcription of genes involved in glucose and lipid homeostasis. The binding of a TZD induces conformational changes that promote the recruitment of coactivator proteins, leading to altered gene expression. Importantly, the therapeutic effects are mediated through both PPARγ-dependent and independent pathways, including modulation of mitochondrial function and anti-inflammatory signaling.

Effects on Adipose Tissue

In adipose tissue, PPARγ activation promotes adipocyte differentiation and lipid storage. This shifts fat accumulation from visceral depots (associated with higher metabolic risk) to subcutaneous depots, which are more insulin-sensitive. TZDs also increase the expression of adiponectin, an adipokine that enhances insulin sensitivity, reduces inflammation, and improves fatty acid oxidation. Adiponectin levels rise two- to three-fold with TZD therapy, and this increase correlates with improved glycemic control. Conversely, TZDs suppress the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and resistin, further attenuating insulin resistance. The reduction in circulating free fatty acids (FFAs) also relieves lipotoxicity in muscle and liver.

Effects on Muscle and Liver

In skeletal muscle, TZDs increase glucose transport by upregulating GLUT4 translocation and enhancing insulin signaling pathways such as IRS-1/PI3K/Akt. They also promote glycogen synthesis and reduce intramyocellular lipid accumulation. In the liver, TZDs reduce gluconeogenesis and increase glycogen synthesis, thereby lowering hepatic glucose output. This is achieved partly through decreased expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase. The net effect is improved peripheral and hepatic insulin sensitivity, leading to better glycemic control. Unlike sulfonylureas or meglitinides, TZDs do not stimulate insulin secretion; they only lower glucose when endogenous insulin is present, making them less likely to cause hypoglycemia as monotherapy. However, when combined with insulin or secretagogues, hypoglycemia risk increases due to additive glucose lowering.

Additional Pleiotropic Effects

Beyond glucose metabolism, TZDs exert anti-inflammatory effects by reducing NF-κB activation and decreasing levels of C-reactive protein (CRP), interleukin-6 (IL-6), and matrix metalloproteinases. They also improve endothelial function, reduce carotid intima-media thickness progression, and may have beneficial effects on blood pressure through PPARγ-mediated vasodilation. Some studies suggest TZDs modestly lower blood pressure by 2–5 mmHg in hypertensive patients with T2DM.

Clinical Benefits Beyond Glycemic Control

The primary clinical benefit of TZDs is sustained improvement in glycemic control. Pioglitazone and rosiglitazone lower hemoglobin A1c by approximately 0.5–1.5%, depending on baseline values and concomitant therapy. Their durability of effect is notable; because they target the underlying insulin resistance rather than forcing beta-cell secretion, the glucose-lowering effect can be maintained longer compared to sulfonylureas. In the ADOPT study (A Diabetes Outcome Progression Trial), rosiglitazone monotherapy delayed the need for additional agents more effectively than metformin or glyburide over five years. Beyond glucose reduction, TZDs offer several other advantages.

Lipid Profile Modifications

Pioglitazone has been shown to reduce triglycerides by 10–20% and increase high-density lipoprotein (HDL) cholesterol by 5–15%, while its effects on low-density lipoprotein (LDL) are variable — often neutral or slightly increased. Rosiglitazone, in contrast, may increase LDL by up to 15% without significant triglyceride reduction. The differential lipid effects have clinical implications, as pioglitazone is generally preferred in patients with mixed dyslipidemia or elevated triglycerides. TZDs also decrease free fatty acid levels, which contributes to improved insulin sensitivity and reduced hepatic steatosis.

Cardiovascular Outcomes

Concerns about cardiovascular safety emerged from meta-analyses of rosiglitazone suggesting an increased risk of myocardial infarction. This led to restricted use and FDA labeling changes in 2010. However, subsequent analyses, including the RECORD trial, did not confirm a significantly elevated risk, and the FDA later removed prescribing restrictions in 2013. However, pioglitazone has been studied more extensively in this context. The PROactive trial (2005) demonstrated a reduction in the composite endpoint of all-cause mortality, nonfatal myocardial infarction, and stroke in high-risk T2DM patients. A 2021 meta-analysis of pioglitazone trials confirmed a 15–20% reduction in major adverse cardiovascular events (MACE). The IRIS trial (2016) showed that pioglitazone reduced the risk of stroke or myocardial infarction in non-diabetic patients with insulin resistance and recent stroke. The difference between the two TZDs is attributed to pioglitazone’s favorable lipid effects and possibly distinct PPARγ modulation. Current guidelines consider pioglitazone as a secondary option after metformin in patients with established cardiovascular disease, especially those who are not at risk for heart failure exacerbation.

Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH

Given its effects on insulin resistance and hepatic fat accumulation, pioglitazone has been studied in non-alcoholic steatohepatitis (NASH). Clinical trials show improvements in histologic markers such as steatosis, inflammation, and ballooning degeneration. The PIVENS trial (2010) demonstrated that pioglitazone improved steatosis and inflammation but not fibrosis in non-diabetic NASH patients. The multi-center FLINT trial and subsequent meta-analyses confirmed that pioglitazone significantly improves NASH resolution and reduces liver fibrosis progression. Although not formally approved for NASH, pioglitazone is sometimes used off-label, particularly in patients with T2DM and biopsy-proven NASH. The effect on fibrosis is less consistent, but ongoing research suggests that longer treatment duration may yield greater antifibrotic benefits.

Effects on Beta-Cell Preservation

By reducing secretory demand on the beta cells, TZDs may help preserve pancreatic function. The TRIPOD study showed that troglitazone reduced the progression to overt diabetes in women with prior gestational diabetes, and the effect persisted years after drug discontinuation. Pioglitazone has similarly been shown to improve HOMA-β scores and delay insulin requirement in T2DM patients. This disease-modifying potential distinguishes TZDs from many other oral agents.

Safety Profile and Adverse Effects

Despite their efficacy, TZDs have significant adverse effects that limit their use in certain populations. The most common and clinically relevant include weight gain, fluid retention, increased fracture risk, and potential cardiovascular concerns. Careful patient selection and monitoring are essential.

Weight Gain and Edema

Weight gain of 2–5 kg on average is common, primarily due to increased adipose tissue mass and fluid retention. Fluid retention results from PPARγ-mediated enhancement of sodium reabsorption in the renal collecting duct via increased expression of the epithelial sodium channel (ENaC). This can lead to peripheral edema, which is dose-dependent and more pronounced in patients also using insulin or sulfonylureas. TZD-induced edema may exacerbate or precipitate heart failure, and TZDs are contraindicated in patients with New York Heart Association (NYHA) class III or IV heart failure. For patients with mild heart failure (NYHA I–II), TZDs should be used cautiously with diuretics and careful monitoring of weight, edema, and dyspnea. The risk of heart failure hospitalization is approximately doubled with TZDs, though mortality in such cases is not increased.

Bone Fractures

TZDs have been associated with an increased risk of fractures, particularly in women. The mechanism involves PPARγ activation in osteoblasts and osteoclasts, altering bone remodeling. Studies show reduced bone mineral density in the hip and spine among female TZD users. Fractures occur predominantly in the distal upper extremities (forearm, hand) and lower extremities (foot, ankle). The risk is higher with longer duration of therapy (>1 year) and in postmenopausal women. Fracture incidence in men is less consistently elevated. Baseline and periodic assessment of fracture risk, including bone mineral density in high-risk women, is recommended. Avoid TZDs in patients with established osteoporosis or history of fragility fractures.

Bladder Cancer Signal

Epidemiologic studies have suggested a possible association between pioglitazone and bladder cancer. The ADOPT trial found a higher number of bladder cancer cases in patients on pioglitazone vs. comparator groups, although subsequent analyses have yielded mixed results. A 2016 meta-analysis of cohort studies reported a modest 15% increased risk, but the association was attenuated in larger database studies. The FDA revised the label to contraindicate use in patients with active bladder cancer and to advise caution in those with a history of bladder cancer. The risk appears to increase with cumulative dose and duration, particularly beyond two years of use. While the absolute risk is low (approximately 1–2 excess cases per 10,000 patient-years), it remains a consideration for long-term therapy, especially in elderly males with other risk factors.

Hepatic Effects

Troglitazone, the first TZD, was withdrawn in 2000 due to rare but severe hepatotoxicity, leading to acute liver failure in about 1 in 20,000 patients. Pioglitazone and rosiglitazone have minimal liver toxicity, with no confirmed cases of drug-induced liver injury in controlled trials. However, periodic monitoring of liver enzymes (ALT, AST) is still recommended, especially in patients with preexisting liver disease. TZDs are contraindicated in patients with active liver disease or ALT >2.5 times the upper limit of normal. In practice, stable NAFLD patients can be treated with pioglitazone, and some studies suggest it may improve liver enzymes.

Macular Edema

Rare cases of new-onset or worsening diabetic macular edema have been reported with TZD use, possibly due to fluid retention. Patients reporting visual changes should be promptly evaluated by an ophthalmologist. The incidence is low, but caution is warranted in patients with preexisting diabetic retinopathy.

Place in Current Treatment Algorithms

Current American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend metformin as first-line therapy for T2DM. For patients who need additional glycemic control or cannot tolerate metformin, TZDs are one of several second-line options. Pioglitazone is preferred over rosiglitazone due to better cardiovascular safety data and favorable lipid effects. TZDs may be particularly useful in patients with significant insulin resistance, such as those with high waist circumference, fatty liver, or metabolic syndrome. They are also a valuable option in patients with cardiovascular disease (especially pioglitazone) and in those needing durable glycemic control without weight neutrality. However, their use is limited in patients with heart failure risk, osteoporosis, or a history of bladder cancer. Combination with GLP-1 receptor agonists or SGLT2 inhibitors is becoming more common, leveraging the complementary mechanisms of these drug classes. For example, adding an SGLT2 inhibitor may offset the weight gain and edema associated with TZDs, while adding a GLP-1 receptor agonist provides additional cardiovascular and weight benefits. TZDs can also delay the need for insulin therapy by preserving beta-cell function through reduced secretory demand. In patients with renal impairment (eGFR <30 mL/min), where many other agents are contraindicated, pioglitazone can be used without dose adjustment.

Comparative Efficacy and Safety with Other Insulin Sensitizers

Metformin also improves insulin sensitivity, but through activation of AMPK rather than PPARγ. Metformin has the advantage of weight neutrality or slight weight loss, lower cost, and a well-established safety profile. However, gastrointestinal side effects occur in up to 20% of patients, and lactic acidosis risk (though rare) limits use in advanced kidney disease. TZDs offer a non-metformin mechanism and can be used even when metformin is contraindicated due to renal impairment or intolerance. In head-to-head trials like ADOPT, rosiglitazone showed better durability of glycemic control than metformin or glyburide, but at the cost of more weight gain and edema. In RECORD, the addition of rosiglitazone to metformin or sulfonylurea provided sustained glucose lowering, though with elevated fracture rates in women. When compared with newer agents such as SGLT2 inhibitors, TZDs have similar glucose-lowering efficacy but lack the cardiovascular and renal benefits seen with empagliflozin or dapagliflozin. However, TZDs are more effective at increasing adiponectin and improving fatty liver. Choosing between these agents depends on individual patient characteristics, comorbidities, and goals of therapy.

Future Directions and Research

Research continues into TZD-like molecules with improved safety profiles. Selective PPARγ modulators (SPPARMs) aim to retain insulin-sensitizing effects while minimizing adverse effects like weight gain, fluid retention, and fractures. For example, INT131 and other compounds are in early clinical development, showing promising glycemic effects with less edema. Dual PPARα/γ agonists (glitazars) have shown mixed results — muraglitazar was not approved due to cardiovascular safety concerns, while saroglitazar is approved in India for diabetic dyslipidemia and NASH. Additionally, the role of TZDs in prediabetes and type 1 diabetes is being investigated. The TRIPOD and DPP trials demonstrated that troglitazone could delay progression from impaired glucose tolerance to T2DM, suggesting a role in prevention. However, safety concerns may limit long-term prophylactic use. Combining TZDs with agents that counteract edema or bone loss, such as SGLT2 inhibitors or bisphosphonates, is another promising avenue. A small study combining pioglitazone and dapagliflozin showed less weight gain and edema compared to pioglitazone alone, while maintaining glucose lowering. Future research will likely focus on patient selection using biomarkers (e.g., adiponectin levels) to identify those most likely to benefit from TZD therapy with minimal risk.

Conclusion

Thiazolidinediones are a unique class of antidiabetic agents that directly target the core pathophysiology of type 2 diabetes: insulin resistance. By activating PPARγ, they enhance glucose uptake in muscle and adipose tissue, suppress hepatic glucose production, and improve lipid metabolism. Their benefits extend beyond glycemic control to include favorable effects on lipid profiles, a reduction in non-alcoholic fatty liver disease markers, and potential cardiovascular benefit with pioglitazone. However, the risk of weight gain, edema, heart failure exacerbation, fractures, and a possible bladder cancer signal necessitates careful patient selection and monitoring. In current clinical practice, TZDs occupy an important role as second- or third-line options, particularly in patients with significant insulin resistance and without contraindications. Ongoing research into SPPARMs and combination therapies holds promise for future improvements in the risk-benefit profile. For now, thiazolidinediones remain a valuable, albeit cautious, addition to the diabetes pharmacopeia.

For further reading, consult the ADA Standards of Care 2025, a comprehensive review of TZDs in the Journal of Clinical Medicine, the IRIS trial results on pioglitazone and stroke risk, and the FDA safety update on pioglitazone and bladder cancer risk.